Interview with Edwin Harvey, Managing Director, Biogen Idec Argentina
Biogen Idec’s arrival in Argentina has been very recent. Could you explain to our readers why the time was right to take back your licences and to set up in…
Address: Av. del Libertador 350 – 7th Floor
1638 Vicente Lopez – Buenos Aires
Argentina
Tel: +54 11 5550 8150
Web: http://www.biogenidec.com/
Biogen Idec Argentina is part of a multinational company, headquartered in Cambridge, Massachusetts which has, since its formation, gained a commercial presence in over 29 markets. Their two leading products, AVONEX and RITUXAN, have for years ranked among the top ten biotechnology products sold globally.
Biogen Idec’s presence in Argentina provides therapeutic solutions through knowledge, research and support programs for the local multiple sclerosis. A great deal of commitment is shown to this new market as investment is flowing in the form of an R&D laboratory. This new venture in Latin America, and offices in Brazil and now Argentina, allows Biogen Idec to reach patients throughout the whole region.
Neurology
Biogen Idec’s arrival in Argentina has been very recent. Could you explain to our readers why the time was right to take back your licences and to set up in…
“In the last decade, as a result of high and sustained growth, the Argentine pharmaceutical industry increased production by more than 240 percent, which speaks volumes about the capacity of…
The country president of AstraZeneca Argentina discusses the country’s patent laws, the work being done to bring innovation back to Argentina, and the challenge of a strong branded generics market…
When we met with Javier Lombar at IMS Argentina, he was explaining how a lot of multinational companies are using Argentina as a regional base of operations. Novartis is a…
Roemmers fue establecida en 1921. ¿Cómo paso de ser una empresa familiar a la empresa que es hoy, y cuáles han sido los desafíos en el cambio en la cultura…
The executive management of Nycomed said in an interview that ‘the tremendous growth of the pharmaceutical industry will not occur in either Europe or the United States, but in emerging…
Could you give us an overview of the generics sector in Argentina as it stands at the moment? The generics market in Argentina was started immediately after the regulation regarding…
Do you think this is a good moment for the Argentinean pharmaceutical industry to have international exposure? Indeed it is attractive, but we should keep the long term objectives on…
What have been the recent major milestones for Richmond? One of the milestones for Laboratorios Richmond was to have developed the first branded oncological generic in the world. For Laboratorios…
Biogen Idec’s arrival in Argentina has been very recent. Could you explain to our readers why the time was right to take back your licences and to set up in…
What was the vision behind the creation of the umbrella organisation Amega Biotech in 2005? What led you to consider setting up an organisation with this structure, and offering these…
Novo Nordisk’s largest insulin production facility outside of Denmark is in Latin America, in Brazil. Can you explain the strategic importance of this for Argentina, and how Novo Nordisk is…
Fundacion Export.Ar was formed in 1993. What was the vision behind the foundation of the company and why was it formed at that specific time? Argentina understood that the country…
See our Cookie Privacy Policy Here
